SCHEMBL1318949

SCHEMBL1318949

CCCCC(C(=O)O)N(c1cccc2c(NC(=O)Cc3ccccc3)cccc12)S(=O)(=O)c1cc(Cl)cc(Cl)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNQ2 O43526 1/20 0.42
PSEN1 P49768 1/20 0.41
PSEN2 P49810 1/20 0.41
APH1B Q8WW43 1/20 0.41
NCSTN Q92542 1/20 0.41
APH1A Q96BI3 1/20 0.41
PSENEN Q9NZ42 1/20 0.41
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38
CA5A P35218 1/20 0.38
CA7 P43166 1/20 0.38
CA5B Q9Y2D0 1/20 0.38
CNR2 P34972 2/20 0.38
GPR35 Q9HC97 1/20 0.37
ALDH1A1 P00352 3/20 0.37
LMNA P02545 1/20 0.36
KCNJ6 P48051 1/20 0.36
KCNJ5 P48544 1/20 0.36
KCNJ3 P48549 1/20 0.36
KDM4E B2RXH2 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1110205 0.92 CA12 (0.42) CA1CA2ALDH1A1LMNAL3MBTL1
SCHEMBL1110284 0.92 PSEN1 (0.42) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL1110472 0.92 POLB (0.47) KCNQ2ALDH1A1LMNAKDM4EGAA
SCHEMBL1110213 0.90 KDM4E (0.42) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL1110187 0.88 GAA (0.45) ALDH1A1LMNAKDM4EGAAHPGD
SCHEMBL1110297 0.88 CA12 (0.41) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL1110475 0.87 MAPT (0.38) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL1319294 0.84 KDM4C (0.38) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL1110368 0.82 PSEN1 (0.40) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL1110456 0.81 MAPT (0.40) CA1ALDH1A1LMNAKDM4EGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110269761-A1 ARYLSULPHONYLGLYCINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-11-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110269761-A1 ARYLSULPHONYLGLYCINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS SULT2A1, UGT1A1, SLC5A1 KCNQ2 2792/4885PSEN1 2282/4885PSEN2 3185/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.